Creative Planning Grows Position in Fresenius Medical Care AG (NYSE:FMS)

Creative Planning increased its position in Fresenius Medical Care AG (NYSE:FMS) by 18.9% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 40,140 shares of the company’s stock after purchasing an additional 6,373 shares during the quarter. Creative Planning’s holdings in Fresenius Medical Care were worth $766,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in FMS. Wulff Hansen & CO. lifted its stake in shares of Fresenius Medical Care by 1,809.0% in the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares during the period. Veracity Capital LLC lifted its stake in shares of Fresenius Medical Care by 172.2% in the 1st quarter. Veracity Capital LLC now owns 53,023 shares of the company’s stock valued at $1,022,000 after purchasing an additional 33,543 shares during the period. Legacy Wealth Asset Management LLC purchased a new position in Fresenius Medical Care during the first quarter valued at $584,000. Triasima Portfolio Management inc. raised its stake in Fresenius Medical Care by 27.4% during the second quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock valued at $1,631,000 after buying an additional 18,360 shares during the last quarter. Finally, Koss Olinger Consulting LLC purchased a new position in Fresenius Medical Care during the second quarter valued at $286,000. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Stock Down 1.4 %

FMS stock opened at $19.60 on Friday. Fresenius Medical Care AG has a 1-year low of $16.37 and a 1-year high of $22.76. The business has a fifty day moving average price of $19.83 and a 200-day moving average price of $20.04. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09. The stock has a market capitalization of $11.50 billion, a P/E ratio of 22.02, a P/E/G ratio of 1.06 and a beta of 0.91.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, hitting the consensus estimate of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The firm had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.28 billion. Equities analysts forecast that Fresenius Medical Care AG will post 1.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on FMS. Truist Financial lifted their price objective on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, October 7th. StockNews.com began coverage on Fresenius Medical Care in a research note on Tuesday, October 8th. They set a “strong-buy” rating for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Fresenius Medical Care currently has a consensus rating of “Hold” and a consensus target price of $23.00.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.